上海交通大学学报（医学版）

上海交通大学学报（医学版） >

2024 , Vol. 44 >Issue 12: 1526 - 1535

DOI: https://doi.org/10.3969/j.issn.1674-8115.2024.12.005

论著 · 基础研究

血管抑制蛋白2在三阴性乳腺癌中的功能及其调控可变剪接机制

  • 王卫 ,
  • 王红丽 ,
  • 阿力比亚提·艾尼 ,
  • 衣力亚尔·肉苏 ,
  • 阿依努尔 ,
  • 杨亮
展开
  • 新疆医科大学附属肿瘤医院头颈外科，乌鲁木齐 830011
王 卫（1996—），男，住院医师，硕士；电子信箱：2449965197@qq.com。
杨 亮，电子信箱：xjzlyangliang@sina.com。

收稿日期: 2024-03-10

  录用日期: 2024-07-10

  网络出版日期: 2024-12-28

基金资助

新疆维吾尔自治区自然科学基金项目(2020D01C211)

收起

Function of vasohibin-2 and the mechanism of alternative splicing in triple-negative breast cancer

  • Wei WANG ,
  • Hongli WANG ,
  • Ain ALIBIYATI·i ,
  • Rousu YILIYAER· ,
  • NUER AYI ,
  • Liang YANG
Expand
  • Department of Head and Neck Surgery, Xinjiang Medical University Affiliated Cancer Hospital, Urumqi 830011, China
YANG Liang, E-mail: xjzlyangliang@sina.com.

Received date: 2024-03-10

  Accepted date: 2024-07-10

  Online published: 2024-12-28

Supported by

Xinjiang Uygur Autonomous Region Natural Science Foundation(2020D01C211)

Fold

摘要

目的·探索血管抑制蛋白2（vasohibin-2，VASH2）在三阴性乳腺癌（triple-negative breast cancer，TNBC）中的表达及VASH2通过调控基因表达和可变剪接在TNBC发生发展中的作用机制。方法·通过基因型-组织表达数据库（Genotype-Tissue Expression，GTEx）联合癌症基因组图谱数据库（The Cancer Genome Atlas，TCGA）比较VASH2在TNBC中与正常乳腺组织中的表达差异，并分析VASH2在TNBC中的甲基化水平。在TNBC细胞系MDA-MB-231中对VASH2过表达，并进行转录组测序，分析受VASH2所调控的差异表达基因及可变剪接基因。结果·VASH2在TNBC组织中与正常组织及其他乳腺癌分型比较表达水平显著提高。VASH2基因的低甲基化可能是VASH2在TNBC 中表达上调的原因之一。VASH2过表达后引起81个基因显著差异表达，其中上调的基因23个，下调的基因58个。VASH2过表达后可变剪接水平发生显著变化的基因主要富集在细胞周期、p53信号通路上。结论·VASH2可能通过调控TNBC中基因可变剪接促进其发生和发展。

关键词： 血管抑制蛋白2; 三阴性乳腺癌; 可变剪接; p53信号通路; 细胞周期

本文引用格式

王卫 , 王红丽 , 阿力比亚提·艾尼 , 衣力亚尔·肉苏 , 阿依努尔 , 杨亮 . 血管抑制蛋白2在三阴性乳腺癌中的功能及其调控可变剪接机制[J]. 上海交通大学学报（医学版）, 2024 , 44(12) : 1526 -1535 . DOI: 10.3969/j.issn.1674-8115.2024.12.005

Abstract

Objective ·To explore the role of vasohibin-2 (VASH2) in the regulation of proliferation and metastasis of triple-negative breast cancer (TNBC) cells, and explore the mechanism of VASH2 in the occurrence and development of TNBC through regulation of gene expression and alternative splicing. Methods ·TCGA-GTEx was used to analyze the expression of VASH2 in TNBC. VASH2 methylation levels in TNBC were also analyzed. VASH2 was overexpressed in the MDA-MB-231 human TNBC cell line and transcriptome sequencing was performed. Differentially expressed genes and alternatively spliced genes regulated by VASH2 were analyzed to explore the mechanism of action of VASH2 in TNBC. Results ·VASH2 was significantly overexpressed in TNBC compared to the normal tissues. Hypomethylation of the VASH2 gene was implicated in the upregulation of VASH2 expression in TNBC. Overexpression of VASH2 caused significant differential expression of 81 genes, of which 23 genes were up-regulated and 58 genes were down-regulated. Genes with significantly altered alternative splicing levels due to VASH2 overexpressed were enriched in cell cycle and p53 signaling pathways. Conclusion ·VASH2 regulates the alternative splicing of TNBC oncogenes and promotes TNBC occurrence and development.

Key words： vasohibin-2 (VASH2); triple-negative breast cancer (TNBC); alternative splicing; p53 signaling pathway; cell cycle

参考文献

1 DERAKHSHAN F, REIS-FILHO J S. Pathogenesis of triple-negative breast cancer[J]. Annu Rev Pathol, 2022, 17: 181-204.
2 ZONG Y, PEGRAM M. Research advances and new challenges in overcoming triple-negative breast cancer[J]. Cancer Drug Resist, 2021, 4(3): 517-542.
3 MERIKHIAN P, EISAVAND M R, FARAHMAND L. Triple-negative breast cancer: understanding Wnt signaling in drug resistance[J]. Cancer Cell Int, 2021, 21(1): 419.
4 BURSTEIN H J, CURIGLIANO G, THüRLIMANN B, et al. Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021[J]. Ann Oncol. 2021,32(10):1216-1235.
5 TU J J, FANG Y L, HAN D F, et al. Activation of nuclear factor-κB in the angiogenesis of glioma: insights into the associated molecular mechanisms and targeted therapies[J]. Cell Prolif, 2021, 54(2): e12929.
6 TAN X B, LIAO Z F, ZOU S Y, et al. VASH2 promotes cell proliferation and resistance to doxorubicin in non-small cell lung cancer via AKT signaling[J]. Oncol Res, 2020, 28(1): 3-11.
7 NINOMIYA Y, OZAWA S, OGUMA J, et al. Expression of vasohibin-1 and-2 predicts poor prognosis among patients with squamous cell carcinoma of the esophagus[J]. Oncol Lett, 2018, 16(4): 5265-5274.
8 SATO Y. The vasohibin family: a novel family for angiogenesis regulation[J]. J Biochem, 2013, 153(1): 5-11.
9 YAMAMOTO M, OZAWA S, NINOMIYA Y, et al. Plasma vasohibin-1 and vasohibin-2 are useful biomarkers in patients with esophageal squamous cell carcinoma[J]. Esophagus, 2020, 17(3): 289-297.
10 KITAHARA S, SUZUKI Y, MORISHIMA M, et al. Vasohibin-2 modulates tumor onset in the gastrointestinal tract by normalizing tumor angiogenesis[J]. Mol Cancer, 2014, 13: 99.
11 NORITA R, SUZUKI Y, FURUTANI Y, et al. Vasohibin-2 is required for epithelial-mesenchymal transition of ovarian cancer cells by modulating transforming growth factor-β signaling[J]. Cancer Sci, 2017, 108(3): 419-426.
12 TU M, LI Z J, LIU X, et al. Vasohibin 2 promotes epithelial-mesenchymal transition in human breast cancer via activation of transforming growth factor β 1 and hypoxia dependent repression of GATA-binding factor 3[J]. Cancer Lett, 2017, 388: 187-197.
13 MA H R, CAO L, WANG F, et al. Filamin B extensively regulates transcription and alternative splicing, and is associated with apoptosis in HeLa cells[J]. Oncol Rep, 2020, 43(5): 1536-1546.
14 YISA S B, FEI W M, YAXUN W M, et al. ATP5A1 participates in transcriptional and posttranscriptional regulation of cancer-associated genes by modulating their expression and alternative splicing profiles in HeLa cells[J]. Technol Cancer Res Treat, 2021, 20: 15330338211039126.
15 沈鑫鑫, 金磊, 赵倩, 等. 血管抑制蛋白2在乳腺癌中的表达情况及其对患者预后的影响[J]. 安徽医学, 2021, 42(2): 144-148.
15 SHEN X X, JIN L, ZHAO Q, et al. Expression of vasohibin-2 and its effect on prognosis of breast cancer[J]. Anhui Medical Journal, 2021, 42(2): 144-148.
16 GAO Y, ZHANG W Z, LIU C W, et al. MiR-200 affects tamoxifen resistance in breast cancer cells through regulation of MYB[J]. Sci Rep, 2019, 9(1): 18844.
17 ZENG X, QU X J, ZHAO C Y, et al. FEN1 mediates miR-200a methylation and promotes breast cancer cell growth via MET and EGFR signaling[J]. FASEB J, 2019, 33(10): 10717-10730.
18 ANSARI J, SHACKELFORD R E, EL-OSTA H. Epigenetics in non-small cell lung cancer: from basics to therapeutics[J]. Transl Lung Cancer Res, 2016, 5(2): 155-171.
19 LI R, YANG Y E, YIN Y H, et al. Methylation and transcriptome analysis reveal lung adenocarcinoma-specific diagnostic biomarkers[J]. J Transl Med, 2019, 17(1): 324.
20 CHEN Y C, LIU X R, LI Y K, et al. Lung cancer therapy targeting histone methylation: opportunities and challenges[J]. Comput Struct Biotechnol J, 2018, 16: 211-223.
21 WANG B, YANG L, ZHAO Q, et al. Vasohibin 2 as a potential predictor of aggressive behavior of triple-negative breast cancer[J]. Am J Transl Res, 2017, 9(6): 2911-2919.
22 LI F X, HU Y J, QI S T, et al. Structural basis of tubulin detyrosination by vasohibins[J]. Nat Struct Mol Biol, 2019, 26(7): 583-591.
23 VAN DER LAAN S, LéVêQUE M F, MARCELLIN G, et al. Evolutionary divergence of enzymatic mechanisms for tubulin detyrosination[J]. Cell Rep, 2019, 29(12): 4159-4171.e6.
24 NIEUWENHUIS J, ADAMOPOULOS A, BLEIJERVELD O B, et al. Vasohibins encode tubulin detyrosinating activity[J]. Science, 2017, 358(6369): 1453-1456.
25 JOERGER A C, FERSHT A R. The p53 pathway: origins, inactivation in cancer, and emerging therapeutic approaches[J]. Annu Rev Biochem, 2016, 85: 375-404.
26 ZHANG H, ZHANG X, LI X, et al. Effect of CCNB1 silencing on cell cycle, senescence, and apoptosis through the p53 signaling pathway in pancreatic cancer[J]. J Cell Physiol, 2018, 234(1): 619-631.
27 MISSAOUI N, LANDOLSI H, MESTIRI S, et al. Immunohistochemical analysis of c-erbB-2, Bcl-2, p53, p21(WAF1/Cip1), p63 and Ki-67 expression in hydatidiformmoles[J]. Pathol Res Pract,2019,215(3):446-452.
28 LO W, PARKHURST M, ROBBINS P F, et al. Immunologic recognition of a shared p53 mutated neoantigen in a patient with metastatic colorectal cancer[J]. Cancer Immunol Res,2019,7(4):534-543.
29 SCHAEFER I M, HORNICK J L, SHOLL L M, et al. Abnormal p53 and p16 staining patterns distinguish uterine leiomyosarcoma from inflammatory myofibroblastic tumour[J]. Histopathology, 2017, 70(7): 1138-1146.
30 DONNELLAN R, CHETTY R. Cyclin E in human cancers[J]. FASEB J, 1999, 13(8): 773-780.
31 KEYOMARSI K, O'LEARY N, MOLNAR G, et al. Cyclin E, a potential prognostic marker for breast cancer[J]. Cancer Res, 1994, 54(2): 380-385.
32 HUANG X, SHAO D, WU H W, et al. Genomic profiling comparison of germline BRCA and non-BRCA carriers reveals CCNE1 amplification as a risk factor for non-BRCA carriers in patients with triple-negative breast cancer[J]. Front Oncol, 2020, 10: 583314.
33 杨睿, 陈俊霞. 环状RNA hsa_circ_0058514在三阴性乳腺癌中的表达及作用研究[J]. 中国癌症杂志, 2019, 29(1): 9-18.
33 YANG R, CHEN J X. Effects of circular RNA hsa_circ_0058514 on the development and progression of triple-negative breast cancer[J]. China Oncology, 2019, 29(1): 9-18.
34 LIU Z, FU Q S, WANG Y, et al. Synergy between vinorelbine and afatinib in the inhibition of non-small cell lung cancer progression by EGFR and p53 signaling pathways[J]. Biomed Pharmacother, 2021, 134: 111144.
Options
文章导航

/

〈 〉